Thrombin generation and atherosclerosis

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 1, 2014, Pages 45-55

  Kalz, Jana ^a   Ten Cate, Hugo ^a   Spronk, Henri M H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Activated protein C; Atherosclerosis; Direct oral anticoagulants; Inflammation; Protease activated receptor; Thrombin

Indexed keywords

ANIMALS; ANTICOAGULANTS; ATHEROSCLEROSIS; HUMANS; THROMBIN;

EID: 84895074815     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1026-5     Document Type: Review

References (73)

1. Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:317-325. doi: 10.1038/nature10146
2. Ionita MG, van den Borne P, Catanzariti LM et al (2010) High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 30:1842-1848. doi: 10.1161/ATVBAHA.110.209296
3. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126. doi: 10.1056/NEJM199901143400207
4. Lahoute C, Herbin O, Mallat Z, Tedgui A (2011) Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 8:348-358. doi: 10.1038/nrcardio.2011.62
5. Cybulsky MI, Jongstra-Bilen J (2010) Resident intimal dendritic cells and the initiation of atherosclerosis. Curr Opin Lipidol 21:397-403. doi: 10.1097/MOL.0b013e32833ded96
6. Hansson GKG (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695. doi: 10.1056/NEJMra043430
7. Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515-581. doi: 10.1152/physrev.00024.2005
8. Borissoff JI, Spronk HMH, Heeneman S, ten Cate H (2009) Is thrombin a key player in the "coagulation-atherogenesis" maze? Cardiovasc Res 82:392-403. doi: 10.1093/cvr/cvp066
9. Weber C, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8:802-815. doi: 10.1038/nri2415
10. Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800-1814. doi: 10.1111/j.1538-7836. 2005.01377.x
11. Kaplan ZS, Jackson SP (2011) The role of platelets in atherothrombosis. Hematol Am Soc Hematol Educ Program 2011:51-61. doi: 10.1182/asheducation-2011. 1.51
12. Khrenov AV, Ananyeva NM, Griffin JH, Saenko EL (2002) Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 12:317-324
13. Borissoff JI, Spronk HMH, ten Cate H (2011) The hemostatic system as a modulator of atherosclerosis. N Engl J Med 364:1746-1760. doi: 10.1056/NEJMra1011670
14. Hackeng TM, Maurissen LFA, Castoldi E, Rosing J (2009) Regulation of TFPI function by protein S. J Thromb Haemost 7(Suppl 1):165-168. doi: 10.1111/j.1538-7836.2009.03363.x
15. Lane DA, Philippou H, Huntington JA (2005) Directing thrombin. Blood 106:2605-2612. doi: 10.1182/blood-2005-04-1710
16. Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:34-45. doi: 10.1038/nri3345
17. Lipinski S, Bremer L, Lammers T et al (2011) Coagulation and inflammation. Hämostaseologie 31:94-104. doi: 10.5482/ha-1134
18. Hayden MS, West AP, Ghosh S (2006) NF-kappaB and the immune response. Oncogene 25:6758-6780. doi: 10.1038/sj.onc.1209943
19. Bajaj MS, Ghosh M, Bajaj SP (2007) Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor: physiologic and pathologic implications. J Thromb Haemost 5:1493-1499. doi: 10.1111/j.1538-7836.2007.02604. x
20. De Jonge E, Dekkers PE, Creasey AA et al (2000) Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95:1124-1129
21. O'Brien M (2012) The reciprocal relationship between inflammation and coagulation. Top Companion Animal Med 27:46-52. doi: 10.1053/j.tcam.2012.06.003
22. Antoniak S, Owens AP, Baunacke M et al (2013) PAR-1 contributes to the innate immune response during viral infection. J Clin Invest 123:1310-1322. doi: 10.1172/JCI66125
23. Webb JH, Blom AM, Dahlbäck B (2002) Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol 169:2580-2586
24. Esmon CT, Xu J, Lupu F (2011) Innate immunity and coagulation. J Thromb Haemost 9(Suppl 1):182-188. doi: 10.1111/j.1538-7836.2011.04323.x
25. Martinod K, Demers M, Fuchs TA et al (2013) Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci USA 110:8674-8679. doi: 10.1073/pnas.1301059110
26. Kannemeier C, Shibamiya A, Nakazawa F et al (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 104:6388-6393. doi: 10.1073/pnas.0608647104
27. Borissoff JI, Joosen IA, Versteylen MO et al (2013) Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.113.301627
28. Borissoff JI, ten Cate H (2011) From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? J Thromb Haemost 9:1791-1794. doi: 10.1111/j.1538-7836.2011.04425.x
29. Fong IW, Chiu B, Viira E et al (1999) De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 67:6048-6055
30. de Kruif MD, van Gorp ECM, Keller TT et al (2005) Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research. Cardiovasc Res 65:317-327. doi: 10.1016/j.cardiores.2004.09.031
31. Ezzahiri R, Stassen FRM, Kurvers HAJM et al (2003) Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur J Vasc Endovasc Surg 26:88-95
32. Dechend R, Maass M, Gieffers J et al (1999) Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 100:1369-1373
33. Kilinc E, Van Oerle R, Borissoff JI et al (2011) Factor XII activation is essential to sustain the procoagulant effects of particulate matter. J Thromb Haemost 9:1359-1367. doi: 10.1111/j.1538-7836.2011.04280.x
34. Hoffmann B, Moebus S, Möhlenkamp S et al (2007) Residential exposure to traffic is associated with coronary atherosclerosis. Circulation 116:489-496. doi: 10.1161/CIRCULATIONAHA.107.693622
35. Victor VM, Rocha M, Solá E et al (2009) Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 15:2988-3002
36. Kilinc E, Rudež G, Spronk H (2011) Cardiovascular effects of inhaled ultrafine and nano-sized particles. Wiley, Hoboken
37. Major CD, Santulli RJ, Derian CK, Andrade-Gordon P (2003) Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol 23:931-939. doi: 10.1161/01.ATV.0000070100.47907.26
38. Ma L, Dorling A (2012) The roles of thrombin and protease-activated receptors in inflammation. Semin Immunopathol 34:63-72. doi: 10.1007/s00281-011-0281-9
39. Lin H, Trejo J (2013) Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling. J Biol Chem 288:11203-11215. doi: 10.1074/jbc.M112.439950
40. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH (1999) Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 84:1186-1193
41. Patterson C, Stouffer GA, Madamanchi N, Runge MS (2001) New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res 88:987-997
42. McCoy KL, Gyoneva S, Vellano CP et al (2012) Protease-activated receptor 1 (PAR1) coupling to G(q/11) but not to G(i/o) or G(12/13) is mediated by discrete amino acids within the receptor second intracellular loop. Cell Signal 24:1351-1360. doi: 10.1016/j.cellsig.2012.01.011
43. -/- mice. Atherosclerosis 205:427-432. doi: 10.1016/j.atherosclerosis.2009.01.018
44. Chen D, Dorling A (2009) Critical roles for thrombin in acute and chronic inflammation. J Thromb Haemost 7(Suppl 1):122-126. doi: 10.1111/j.1538-7836. 2009.03413.x
45. Feistritzer C, Lenta R, Riewald M (2005) Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost 3:2798-2805. doi: 10.1111/j.1538-7836.2005.01610.x
46. Esmon CT (2012) Protein C anticoagulant system - anti-inflammatory effects. Semin Immunopathol 34:127-132. doi: 10.1007/s00281-011-0284-6
47. Bouwens EAM, Stavenuiter F, Mosnier LO (2013) Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 11(Suppl 1):242-253. doi: 10.1111/jth.12247
48. Matsumoto K, Yano Y, Gabazza EC et al (2007) Inverse correlation between activated protein C generation and carotid atherosclerosis in Type 2 diabetic patients. Diabet Med 24:1322-1328. doi: 10.1111/j.1464-5491.2007.02289.x
49. Wilcox JN, Noguchi S, Casanova JR, Rasmussen ME (2001) Extrahepatic synthesis of FVII in human atheroma and smooth muscle cells in vitro. Ann N Y Acad Sci 947:433-438
50. Borissoff JI, Heeneman S, Kilinc E et al (2010) Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 122:821-830. doi: 10.1161/CIRCULATIONAHA.109.907121
51. Loeffen R, Spronk HMH, ten Cate H (2012) The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost 10:1207-1216. doi: 10.1111/j.1538-7836.2012.04782.x
52. Borissoff JI, Joosen IA, Versteylen MO et al (2012) Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis. JCMG 5:1201-1210. doi: 10.1016/j.jcmg.2012.01.023
53. Konings J, Govers-Riemslag JWP, Philippou H et al (2011) Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 118:3942-3951. doi: 10.1182/blood-2011-03-339572
54. Nelken NA, Soifer SJ, O'Keefe J et al (1992) Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90:1614-1621. doi: 10.1172/JCI116031
55. Colotta F, Sciacca FL, Sironi M et al (1994) Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 144:975-985
56. Gu L, Okada Y, Clinton SK et al (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275-281
57. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897. doi: 10.1038/29788
58. Minami T, Sugiyama A, Wu S-Q et al (2004) Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 24:41-53. doi: 10.1161/01.ATV.0000099880.09014.7D
59. Naldini A, Carney DH, Pucci A et al (2000) Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1. Gen Pharmacol 35:255-259
60. Shpacovitch VM, Brzoska T, Buddenkotte J et al (2002) Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol 118:380-385. doi: 10.1046/j.0022-202x.2001.01658.x
61. Dabbagh K, Laurent GJ, McAnulty RJ, Chambers RC (1998) Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. Thromb Haemost 79:405-409
62. Kastl SP, Speidl WS, Katsaros KM et al (2009) Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood 114:2812-2818. doi: 10.1182/blood-2009-01-200915
63. Levi M, van der Poll T (2008) The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 34:459-468. doi: 10.1055/s-0028-1092876
64. Borissoff JI, Otten JJT, Heeneman S et al (2013) Genetic and pharmacological modifications of thrombin formation in apolipoprotein E-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS ONE 8:e55784. doi: 10.1371/journal.pone. 0055784.s008
65. Khallou-Laschet J, Caligiuri G, Tupin E et al (2005) Role of the intrinsic coagulation pathway in atherogenesis assessed in hemophilic apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 25:e123-e126. doi: 10.1161/01.ATV.0000171995.22284.9a
66. Tilley RER, Pedersen BB, Pawlinski RR et al (2006) Atherosclerosis in mice is not affected by a reduction in tissue factor expression. Arterioscler Thromb Vasc Biol 26:555-562. doi: 10.1161/01.ATV.0000202028.62414.3c
67. Vicente CP, He L, Tollefsen DM (2007) Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood 110:4261-4267. doi: 10.1182/blood-2007-04-086611
68. Westrick RJ, Bodary PF, Xu Z et al (2001) Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 103:3044-3046
69. Bea F, Kreuzer J, Preusch M et al (2006) Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 26:2787-2792. doi: 10.1161/01.ATV.0000246797.05781.ad
70. Burghaus R, Coboeken K, Gaub T et al (2011) Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS ONE 6:e17626. doi: 10.1371/journal.pone.0017626
71. Zhou Q, Bea F, Preusch M et al (2011) Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011:432080. doi: 10.1155/2011/432080
72. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151. doi: 10.1056/NEJMoa0905561
73. Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9-19. doi: 10.1056/NEJMoa1112277